Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

Company Overview

Prestige Consumer Healthcare Inc. (NYSE: PBH) is a consumer healthcare company that develops, markets and distributes over-the-counter (OTC) products and household health-care brands. Its portfolio includes products for eye care, oral care, gastrointestinal health, pain relief, respiratory health, women’s health, and other everyday health needs.

The company’s brands include Dramamine, Bonine, BC, Goody’s, Clear Eyes, TheraTears, Monistat, Summer’s Eve, Vagisil, Luden’s, Chloraseptic, Compound W, Fleet and Debrox. Prestige generally focuses on established, recognizable brands that are sold through drugstores, mass merchants, grocery stores, e-commerce channels and other retail outlets.

Prestige Consumer Healthcare traces its origins to the acquisition and development of consumer health brands and has expanded primarily through brand acquisitions. The company serves consumers principally in the United States and Canada, with select products distributed in international markets. It is headquartered in Tarrytown, New York.

Key Stats

• Today's Range: $44.77 to $45.88
• 50-Day Range: $44.68 to $54.92
• 52-Week Range: $42.62 to $71.07
• Volume: 604,369 shs
• Average Volume: 613,367 shs
• Market Capitalization: $2.16 billion
• P/E Ratio: 12.76
• Dividend Yield: N/A
• Price Target: $67.67
• Consensus Rating: Hold

Prestige Consumer Healthcare Stock Analysis - MarketRank™

Prestige Consumer Healthcare scored higher than 74% of companies evaluated by MarketBeat, and ranked 114th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Prestige Consumer Healthcare has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Prestige Consumer Healthcare has a consensus price target of $67.67, representing about 48.5% upside from its current price of $45.56.

Amount of Analyst Coverage

Prestige Consumer Healthcare has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.62%

Earnings Growth

Earnings for Prestige Consumer Healthcare are expected to grow by 11.62% in the coming year, from $4.56 to $5.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prestige Consumer Healthcare is 12.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prestige Consumer Healthcare is 12.76, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.32.

Price to Earnings Growth Ratio

Prestige Consumer Healthcare has a PEG Ratio of 1.42. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Prestige Consumer Healthcare has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.27% of the float of Prestige Consumer Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 9.45.

Change versus previous month

Short interest in Prestige Consumer Healthcare has recently increased by 4.57%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

Prestige Consumer Healthcare does not currently pay a dividend.

Dividend Growth

Prestige Consumer Healthcare does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Prestige Consumer Healthcare will have a dividend payout ratio of 37.33% next year. This indicates that Prestige Consumer Healthcare will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.47

News Sentiment

Prestige Consumer Healthcare has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Prestige Consumer Healthcare this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for PBH on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Prestige Consumer Healthcare to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prestige Consumer Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Prestige Consumer Healthcare is held by insiders.

Percentage Held by Institutions

99.95% of the stock of Prestige Consumer Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PBH
• CIK: 1295947
• Web: www.prestigebrands.com
• Phone: (914) 524-6800
• Fax: 302-674-5266
• Employees: 890
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Prestige Consumer Healthcare: $67.67
• High Price Target: $72.00
• Low Price Target: $65.00
• Potential Upside/Downside: +48.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.57
• Trailing P/E Ratio: 12.76
• Forward P/E Ratio: 9.99
• P/E Growth: 1.42
• Net Income: $190.30 million
• Net Margins: 15.57%
• Pretax Margin: 21.20%
• Return on Equity: 11.39%
• Return on Assets: 5.66%

Debt

• Debt-to-Equity Ratio: 1.06
• Current Ratio: 3.23
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: $1.09 billion
• Price / Sales: 1.98
• Cash Flow: $5.24 per share
• Price / Cash Flow: 8.69
• Book Value: $39.89 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 47,380,000
• Free Float: 46,664,000
• Market Cap: $2.16 billion
• Optionable: Optionable
• Beta: 0.34